List view / Grid view
29 April 2025 | By LevitasBio
Join us for a special webinar featuring Young Kim, titled ‘Sample Prep 2.0: A New Paradigm for Biopharma Research’. He will present an overview of the importance of cell sample prep and how challenges of scaling this up faced by biopharma can be addressed using an innovative, label-free approach called…
Learn how to simplify the entire DNA template generation workflow, streamlining mRNA therapeutic research.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
21 March 2025 | By Abzena
Join our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
UBneuro scientists discovered that reducing RTP801 expression prevented cognitive deficits and inflammation.
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Tune into this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
Researchers have obtained images with a previously unseen level of detail, demonstrating how RNA polymerase opens the transcription bubble.
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
In this Q&A, Pascaline Lécorché, Head of Chemical Biology at Vect-Horus, outlines the potential of RNA interference therapeutics and the challenges of their use in vivo. There are several strategies to overcome these, and why peptide-based vectors targeting the LDL receptor are a promising approach.
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy.
Researchers have identified that gestational diabetes is associated with a deficit in placental expression of IGFBP1.
